Regimen Reference Order – BRST – PACLitaxel + trastuzumab

ARIA: BRST - [PACLitaxel + tras (ADJ)]

Planned Course: PACLitaxel and trastuzumab every week for 12 weeks (1 cycle = 21 days), followed by trastuzumab every 21 days for 14 cycles

Indication for Use: Breast Cancer Adjuvant HER2 positive

CVAD: At Provider's Discretion

Proceed with treatment if:

Cycles 1 to 4 (PACLitaxel + trastuzumab)

- ANC equal to or greater than 1×10^9 /L AND Platelets equal to or greater than 100×10^9 /L
- Cycle 5 (trastuzumab every 21 days)
- Blood work at provider's discretion: not required to proceed with treatment
 - Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements		
Drug	Dose	CCMB Administration Guideline
	N	lot Applicable

Establish primary solution 500 mL of: normal saline				
Drug	Dose	CCMB Administration Guideline		
Cycle 1				
Day 1				
trastuzumab (brand	4 mg/kg	IV in normal saline 250 mL over 90 minutes		
name specific)	Loading Dose	*Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order		
		*Nursing Alert: PACLitaxel infusion begins after observation period is complete		
cetirizine	20 mg	Orally 1 hour prior to PACLitaxel		
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes <u>1 hour</u> prior to PACLitaxel		
		*Nursing Alert: PACLitaxel starts 1 hour after completion of dexamethasone infusion		
Wait 1 hour after com	pletion of IV pre-med	ication(s) before starting PACLitaxel		
PACLitaxel	80 mg/m ²	IV in normal saline 250 mL over 1 hour, following the administration rates below:		
		Administer at 100 mL/hour for 15 minutes, then		
		Administer remaining volume over 45 minutes		

		Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter *Nursing Alert: Gently invert bag 8 to 10 times immediately prior to administration of BACLitaval to avenue distribute the drug
Days 8 and 15		to administration of PACLitaxel to evenly distribute the drug
trastuzumab (brand	2 mg/kg	IV in normal saline 250 mL over 30 minutes
name specific)	2 mg/ kg	*Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order
cetirizine	20 mg	Orally 1 hour prior to PACLitaxel
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes <u>1 hour</u> prior to PACLitaxel
		*Nursing Alert: PACLitaxel starts 1 hour after completion of dexamethasone infusion
Wait 1 hour after com	pletion of IV pre-me	dication(s) before starting PACLitaxel
PACLitaxel	80 mg/m ²	IV in normal saline 250 mL over 1 hour, following the administration rates below:
		Administer at 100 mL/hour for 15 minutes, then
		Administer remaining volume over 45 minutes
		Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter
		*Nursing Alert: Gently invert bag 8 to 10 times immediately prior to administration of PACLitaxel to evenly distribute the drug
Cycles 2 to 4		
Days 1, 8 and 15		
trastuzumab (brand	2 mg/kg	IV in normal saline 250 mL over 30 minutes
name specific)		*Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order
cetirizine	20 mg	Orally 1 hour prior to PACLitaxel
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes <u>1 hour</u> prior to PACLitaxel
		*Nursing Alert: PACLitaxel starts 1 hour after completion of dexamethasone infusion
Wait 1 hour after com	pletion of IV pre-me	dication(s) before starting PACLitaxel
PACLitaxel	80 mg/m ²	IV in normal saline 250 mL over 1 hour, following the administration rates below:
		Administer at 100 mL/hour for 15 minutes, then
		Administer remaining volume over 45 minutes
		Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter
		*Nursing Alert: Gently invert bag 8 to 10 times immediately prior to administration of PACLitaxel to evenly distribute the drug



Cycle 5 – trastuzumab every 21 days		
trastuzumab (brand name specific)	6 mg/kg	IV in normal saline 250 mL over 30 minutes every 21 days for 14 doses
		*Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order

All doses will be automatically rounded that fall within CCMB Approved Dose Bands. See Dose Banding document for more information

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

Cardiac monitoring

• Left Ventricular Ejection Fraction (LVEF) monitoring is recommended at baseline and every 3 months

Cycle 1

Day 1

- CBC, biochemistry and liver enzymes as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- Observe patient for 30 minutes after administration of trastuzumab (first dose). Full vital signs after observation period is complete. PACLitaxel infusion begins after observation period is complete
- No observation period required after PACLitaxel administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Days 8 and 15

- CBC as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period required after trastuzumab or PACLitaxel administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Cycles 2 to 4

Day 1

- CBC, biochemistry and liver enzymes as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period required after trastuzumab or PACLitaxel administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Days 8 and 15

- CBC as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period required after trastuzumab or PACLitaxel administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Cycle 5 (trastuzumab every 21 days)

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period required after trastuzumab administration. Patient can be discharged from treatment room if stable whether they had a reaction or not



Recommended Support Medications					
Drug	Dose	CCMB Administration Guideline			
Cycles 1 to 4 ONLY – PACLitaxel + trastuzumab					
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting			

DISCHARGE INSTRUCTIONS

All Cycles

• Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge

Cycles 1 to 4 (PACLitaxel + trastuzumab)

- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- PACLitaxel may cause progressive, irreversible neuropathy
- Reassess trastuzumab dose with significant weight changes
- trastuzumab is available from more than one manufacturer and uses several different brand names. Brand name will be indicated in brackets after trastuzumab. Ensure prescription label matches the brand name on prescribed order
- Note: At Cycle 4, an entry called "*Physician Reminder Order remaining trastuzumab 1 Units Insert Miscellaneous Once*" will appear in the electronic drug order. No action is required. This prompt is to remind the prescriber to order single agent trastuzumab which begins at Cycle 5
- Note: Cycle 5 begins 7 days after Cycle 4, Day 15

